FDA Rejects Biohaven's Troriluzole for Rare Neurological Disease, Company Slashes R&D Budget

FDA denies Biohaven's troriluzole approval for spinocerebellar ataxia citing real-world evidence concerns. Company cuts R&D spending 60% and refocuses on three key late-stage programs.